Brian I. Rini, Vivian Weinberg, Sarah Dunlap, Alexandra Elchinoff, Nancy Yu, Robert Bok, Jeffery Simko and Eric J. Small Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma Cancer 106
Article first published online: 20 DEC 2005 | DOI: 10.1002/cncr.21661
Interferon-alpha (IFNα) and celecoxib, an oral cyclooxygenase-2 (COX-2) inhibitor, were given to metastatic renal cell carcinoma (RCC) patients in a Phase II trial. The addition of celecoxib to IFNα did not increase the objective response rate or time to progression of the unselected cohort. Objective responses and longer time to disease progression (TTP) were observed, however, in the subset of patients with maximal (3+) COX-2 tumor immunostaining. Further investigation of this combination in 3+ COX-2 overexpressing RCC tumors is warranted.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.